PHAT - Phathom Pharmaceuticals, Inc.
IEX Last Trade
6.62
0.200 3.021%
Share volume: 1,191,003
Last Updated: Mon 13 Jan 2025 10:00:00 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.28%
PREVIOUS CLOSE
CHG
CHG%
$6.42
-0.32
-0.05%
View ratios
| Fiscal Date | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 2024-06-14 | 2023-08-10 | 2023-11-09 | 2024-11-07 | 2024-06-14 | 2024-08-08 | 2024-11-07 | |
| Assets | ||||||||
| Total Assets | 144.010 M | 265.039 M | 236.992 M | 413.842 M | 356.499 M | 319.376 M | 387.044 M | |
| Current Assets | 139.843 M | 257.718 M | 226.726 M | 397.432 M | 340.314 M | 304.788 M | 373.821 M | |
| Inventories | 0.000 | 111.000 K | 111.000 K | 1.208 M | 1.458 M | 2.177 M | 3.111 M | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 129.574 M | 248.847 M | 213.677 M | 381.393 M | 322.229 M | 276.237 M | 334.678 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 1.275 M | 1.158 M | 1.976 M | 2.146 M | 1.962 M | 1.813 M | 1.655 M | |
| Other Assets | 2.892 M | 6.163 M | 8.290 M | 11.401 M | 11.356 M | 9.912 M | 8.706 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 144.010 M | 265.039 M | 236.992 M | 413.842 M | 356.499 M | 319.376 M | 387.044 M | |
| Total liabilities | 234.205 M | 247.439 M | 254.765 M | 486.601 M | 505.002 M | 553.205 M | 574.156 M | |
| Total current liabilities | 14.443 M | 21.545 M | 23.979 M | 38.781 M | 43.459 M | 47.009 M | 65.288 M | |
| Accounts Payable | 4.805 M | 4.174 M | 5.794 M | 12.601 M | 8.403 M | 7.656 M | 7.133 M | |
| Other liabilities | 123.124 M | 8.289 M | 8.128 M | 10.162 M | 9.992 M | 10.583 M | 10.750 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 96.638 M | 97.806 M | 99.259 M | 137.842 M | 149.023 M | 174.423 M | 175.729 M | |
| Other liabilities | 123.124 M | 8.289 M | 8.128 M | 10.162 M | 9.992 M | 10.583 M | 10.750 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -90.195 M | 17.600 M | -17.773 M | -72.759 M | -148.503 M | -233.829 M | -187.112 M | |
| Common stock | 674.712 M | 823.472 M | 831.342 M | 855.926 M | 863.034 M | 869.154 M | 1.001 B | |
| Retained earnings | -764.907 M | -805.872 M | -849.115 M | -928.685 M | -1.012 B | -1.103 B | -1.189 B |